This activity provides an overview of CAR T-cell development, available CAR T-cell products for blood cancers, and important side effects of CAR T-cell therapy.
This activity will cover the latest advancements in biology and treatments for acute myeloid leukemia, aggressive lymphoma, and myeloma. The development and practical applications for CAR T-cell therapy in blood cancers is presented. A review of data from the Leukemia & Lymphoma Society patient registry on SARS-CoV-2 vaccination and antibody response in patients with blood cancer provides a glimpse of unmet needs in this vulnerable patient population.
Upon completion of this activity, participants should be better able to:
Upon completion of this activity, participants should be better able to:
Richard W. Vague Professor, Immunotherapy
Director, Center for Cellular Immunotherapies
Director, Parker Institute for Cancer Immunotherapy
University of Pennsylvania
Perelman School of Medicine
Philadelphia, PA
Featured RMEI CE Activities – Earn CE Credit(s)
Stay up to date with the latest RMEI CE Activities and receive Exclusive Medical Education Resources
